0001209191-22-028679.txt : 20220512 0001209191-22-028679.hdr.sgml : 20220512 20220512200113 ACCESSION NUMBER: 0001209191-22-028679 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220510 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galindo Alejandro CENTRAL INDEX KEY: 0001821447 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 22919716 MAIL ADDRESS: STREET 1: 30930 RUSSELL RANCH RD STREET 2: STE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 BUSINESS PHONE: 818-661-5000 MAIL ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-10 0 0000899460 MANNKIND CORP MNKD 0001821447 Galindo Alejandro 1 CASPER STREET DANBURY CT 06810 0 1 0 0 EVP Endocrine Business Unit Restricted Stock Unit 2022-05-10 4 A 0 90000 0.00 A 666690 D Restricted Stock Unit 2022-05-10 4 A 0 110000 0.00 A 776690 D Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. /s/ Alejandro Galindo 2022-05-12